Abstract
Bevacizumab plus either FOLFOX-4 (oxaliplatin, folinic acid, and infusional 5-fluorouracil) or XELOX-2 (capecitabine plus oxaliplatin) is among standard first-line treatment options in patients with metastatic colorectal cancer. This phase II randomized non-comparative trial evaluated the first-line combination of bevacizumab with either FOLFOX-4 or biweekly XELOX-2 in patients with metastatic colorectal cancer. Comparable response and a better tolerability for bevacizumab plus XELOX-2 was reported.
Original language | English |
---|---|
Pages (from-to) | 109-115 |
Number of pages | 7 |
Journal | Clinical Colorectal Cancer |
Volume | 19 |
Issue number | 2 |
DOIs | |
Publication status | Published - Jun 2020 |
Keywords
- Capecitabine
- Elderly
- Fluoropyrimidine
- Frail
- Non-comparative
ASJC Scopus subject areas
- Oncology
- Gastroenterology